News about Global Pharma

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

Pfizer and Chinese biopharmaceutical company 3SBio have entered into a licensing agreement valued at approximately USD 6 billion for the development, manufacturing, and commercialisation of SSGJ-707, a drug candidate targeting various cancers.

Global Pharma | 22/05/2025 | By Manvi |  487

Lilly's Kisunla (donanemab) Secures Marketing Authorisation in Australia for Treatment of Early Symptomatic Alzheimer's Disease

Eli Lilly’s Kisunla (donanemab) has received marketing authorisation from Australia’s Therapeutic Goods Administration (TGA), becoming the country’s first approved amyloid-targeting treatment for early Alzheimer’s disease.

Global Pharma | 22/05/2025 | By Manvi |  212

Tampa General Elevates Heart Care with AI-Powered 512-Slice CT Scanners from GE Healthcare

The advanced scanners leverage artificial intelligence (AI) and machine learning technologies to deliver faster, clearer and more precise scans, refining diagnoses and treatments of cardiovascular diseases.

Global Pharma | 22/05/2025 | By Manvi |  316

OMRON Launches AI-Enabled BP Monitors with Built-In AFib Detection

OMRON Healthcare introduced home blood pressure monitors with built-in AI-powered detection of atrial fibrillation.

Global Pharma | 22/05/2025 | By Manvi |  724

SK Bioscience Prevails in Patent Dispute Against Pfizer Over Pneumococcal Vaccine

SK bioscience has won a major patent lawsuit filed by Pfizer, with the Supreme Court of Korea ruling that SK's pneumococcal vaccine exports did not infringe on Pfizer’s Prevnar 13 patent, clearing the way for renewed global business expansion.

Global Pharma | 22/05/2025 | By Manvi |  413

TheraLight Launches 360i System with PBM, PEMF, and ART Therapies

TheraLight, LLC announces the launch of the TheraLight 360i, a next-generation whole body therapy system that uniquely integrates three advanced, non-invasive therapeutic modalities: Photobiomodulation (PBM), Pulsed Electromagnetic Field (PEMF) Therapy, and Acoustic Resonance Therapy (ART).

Global Pharma | 21/05/2025 | By Manvi |  444

Brainomix Appoints Khush F. Mehta as Chair to Support Global Expansion and Commercial Growth

Brainomix announced the appointment of Khush F. Mehta as Chair of the Board. He succeeds Professor Jacqueline ('Jackie') Hunter CBE, who has served as Chair for the past five years.

Global Pharma | 21/05/2025 | By Manvi |  146

Torrent Pharmaceuticals Appoints Aman Mehta as Managing Director

Torrent Pharmaceuticals has appointed Aman Mehta as Managing Director. His experience includes successful integration of acquisitions and strategic roles across Torrent Group's diverse sectors.

Global Pharma | 21/05/2025 | By Manvi |  1080

Hyalex Orthopaedics Receives FDA Approval to Advance Freestyle Knee Implant to Pivotal Trial

This approval paves the way for Hyalex to expand its Early Feasibility Study (EFS) into a pivotal clinical trial of its novel knee implant technology, supporting the company's continued efforts to bring this next-generation orthopedic solution to patients in need.

Global Pharma | 20/05/2025 | By Manvi |  358

Steven Johnson Joins Zealand Pharma as Chief Development Officer

Zealand Pharma has appointed Steven Johnson as Chief Development Officer to lead regulatory and development strategies, bolstering its leadership team as it advances innovation in obesity and metabolic disease management.

Global Pharma | 20/05/2025 | By Manvi |  480